UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000048420
Receipt number R000055117
Scientific Title Pathophysiology of bronchopulmonary dysplasia focusing on the IL-33 pathway
Date of disclosure of the study information 2022/08/01
Last modified on 2024/01/21 09:49:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Pathophysiology of bronchopulmonary dysplasia focusing on the IL-33 pathway

Acronym

Pathophysiology of bronchopulmonary dysplasia focusing on the IL-33 pathway

Scientific Title

Pathophysiology of bronchopulmonary dysplasia focusing on the IL-33 pathway

Scientific Title:Acronym

Pathophysiology of bronchopulmonary dysplasia focusing on the IL-33 pathway

Region

Japan


Condition

Condition

Bronchopulmonary dysplasia

Classification by specialty

Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To determine the relationship between the IL-33 pathway and bronchopulmonary dysplasia in preterm infants.

Basic objectives2

Others

Basic objectives -Others

To clarify the role of cytokines such as IL-6, IL-8, VEGF, and TNF-alpha in the acute phase as biomarkers of bronchopulmonary dysplasia.

Trial characteristics_1

Exploratory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Serum IL-33 concentration at corrected 36 weeks

Key secondary outcomes

IL-33 pathway IL-4, IL-5, IL-13, TSLP at corrected 36 weeks; IL-6, IL-8, VEGF, TNF-alpha and other cytokines in the acute phase.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

1 days-old <=

Age-upper limit

4 months-old >=

Gender

Male and Female

Key inclusion criteria

Preterm infants born at less than 30 weeks gestation requiring ventilatory support such as ventilatory mechanical ventilation, continuous positive airway pressure, high flow nasal cannula etc.

Key exclusion criteria

congenital multiple malformation syndrome, chromosome abnormalities, congenital airway malformations

Target sample size

110


Research contact person

Name of lead principal investigator

1st name Maki
Middle name
Last name Urushihara

Organization

Tokushima University Hospital

Division name

Department of pediaircs

Zip code

770-8503

Address

Kuramotocho-3chome 18-15, Tokushima City

TEL

+81-88-633-7135

Email

urushihara@tokushima-u.ac.jp


Public contact

Name of contact person

1st name Kenichi
Middle name
Last name Suga

Organization

Tokushima University Hospital

Division name

Department of pediatrics

Zip code

770-8503

Address

Kuramotocho-3chome 18-15, Tokushima City

TEL

+81-88-633-7135

Homepage URL


Email

suga.kenichi.1@tokushima-u.ac.jp


Sponsor or person

Institute

Tokushima University Hospital

Institute

Department

Personal name



Funding Source

Organization

Tokushima University Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

the Ethics Committee of Tokushima University Hospital

Address

Kuramotocho-3chome 18-15, Tokushima City

Tel

+81-88-633-9294

Email

awachiken@tokushima-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

香川大学(香川県)高知大学(高知県)愛媛大学(愛媛県)
四国こどもとおとなの医療センター(香川県)高知医療センター(高知県)
愛媛県立中央病院(愛媛県)


Other administrative information

Date of disclosure of the study information

2022 Year 08 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2022 Year 07 Month 20 Day

Date of IRB

2022 Year 09 Month 28 Day

Anticipated trial start date

2022 Year 09 Month 01 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

-mail  c-akiyoshi-shin@eph.pref.ehime.jp

The purpose of this study is to clarify the association between the development of bronchopulmonary dysplasia in preterm infants and cytokines in the IL-33 pathway. In a collaborative study with major NICU facilities in Shikoku, we will compare serum IL-33 concentrations at corrected 36 weeks between groups of preterm infants requiring respiratory support who are born at less than 30 weeks' gestation and those who does not develop chronic lung disease as the primary endpoint. The secondary endpoint will be the IL-33 pathway including IL-4, IL-5, IL-13, and TSLP at 36 weeks by multiplex assay. Cytokines such as IL-6, IL-8, VEGF, and TNF-alpha in the acute phase will also be examined as biomarkers of bronchopulmonary dysplasia . If the relationship between IL-33 pathway and bronchopulmonary dysplasia is clarified by this study, IL-33 antibody (Itepekimab) and IL-4/13 antibody (Dupilumab) targeting IL-33 pathway may be candidates for treatment and may improve the prognosis of bronchopulmonary dysplasia .


Management information

Registered date

2022 Year 07 Month 21 Day

Last modified on

2024 Year 01 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055117


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name